Hims(US:HIMS) First Shanghai Securities·2025-08-08 09:34Investment Rating - The report maintains a "Buy" rating for HIMS & HERS HEALTH with a target price of $62.1, indicating a potential upside of 22% from the current price of $51.05 [4][6]. Core Insights - The company reported a 73% year-over-year revenue increase in Q2 2025, reaching $545 million, although it experienced a 7% quarter-over-quarter decline. GLP-1 revenue accounted for approximately $200 million, while non-GLP-1 revenue grew by about 16% [2][3]. - The company is transitioning from a model focused on treating diseases to one that emphasizes disease prevention, aiming for $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030 [4]. Summary by Sections Financial Performance - Q2 2025 net profit was $42.51 million, with a net profit margin increase of 3.6 percentage points to 7.8%. Adjusted EBITDA was $82.24 million, with an adjusted EBITDA margin increase of 2.6 percentage points to 15.1% [2]. - The company expects Q3 revenue to be between $570 million and $590 million, with adjusted EBITDA projected at $60 million to $70 million [2]. Business Development - As of Q2 2025, the company had 2.44 million subscribers, a 31% year-over-year increase, with personalized subscription users growing by 89% to 1.48 million [3]. - The company plans to launch new services in low testosterone and menopause care by the end of 2025 and aims to expand into longevity-focused health management [3]. Market Expansion - HIMS & HERS completed the acquisition of ZAVA Global, a leading digital health service provider in Europe, which is expected to contribute at least $50 million in incremental revenue for the remainder of 2025 [3]. - The company anticipates leveraging the expiration of the semaglutide patent in Canada to introduce its weight loss services in that market [3].